Adsa Logo White Adsa Title White

The use of OmniGen-AF in New Zealand dairy herds: An observational study.

M. Gorocica



Join M. Gorocica on this page for a live text chat!
6:00 PM - 8:00 PM GMT


The use of OmniGen-AF in New Zealand dairy herds: An observational study.
B. J. McKay1, J. F. Penry5, N. Chrystal2, M. Gorocica*3, L. O. Tedeschi4. 1Dairy Production Systems LTD Hamilton, New Zealand, 2Complete Feed Solutions LTD Auckland, New Zealand, 3Phibro Animal Health Corporation Teaneck, NJ, 4Texas A&M University College Station, TX, 5Anexa Veterinary Services Morrinsville, New Zealand.

Six dairy farms in New Zealand were selected based on data recording and the availability of feed pad systems for an observational study. The health and milk production were measured on grazing animals that received OmniGen-AF (OG), a nutritional supplement designed to support a healthy immune function in cattle. All herds were seasonal, spring calving herds. A partial mixed ration (PMR) was delivered with a mixer wagon onto a concrete feed pad. OmniGen-AF was included in the PMR at an estimated daily feeding rate of 9 g OG / 100 kg BW from 3 weeks before calving to 100—160 DIM. Data on milk production and bulk tank somatic cell count (BTSCC) was collated from the calving start date to 160 DIM. The incidence rates of lameness and mastitis were estimated from each farm's records sheet. The diagnosis of these diseases was made directly by on-farm personnel. Milk solids production, BTSCC and health outcomes from the current season (CUR, July—December, 2018) and the average of the 2 previous seasons for milk and BTSCC (PREV, July—December, 2016, 2017) or last season (July—December, 2017) for health outcomes, were evaluated. Milk solid production was analyzed using a paired t-test analysis. Beta-regression was used for analyzing mastitis and lameness rate, and binomial regression was used for BTSCC. On average, milk solids production increased by 6% (1.75 vs. 1.65 kg/d, for CUR vs PREV, respectively, P = 0.04). The BTSCC was not different (P = 0.34) but numerically reduced by 18% across all farms in CUR vs. PREV. The mastitis incidence was not different (5.8 vs. 6.8, for CUR vs PREV, respectively, P = 0.69) but lameness rate was decreased (P = 0.04) by 62% (7.9 vs. 15.9 for CUR vs PREV, respectively). Differences on other health indicators were not consistent among farms. The observed reductions in lameness, and increased milk solids production in CUR vs. PREV, suggest that OmniGen supplementation may have assisted in improving health and productivity in these New Zealand farms

Keywords: OmniGen-AS, New Zealand, immunity.